Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 661 to 675 of 1688 results for carers

  1. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975

    Awaiting development [GID-TA11497] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Botulinum toxin type A for preventing episodic migraine ID 6450

    Awaiting development [GID-TA11505] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437

    Awaiting development [GID-TA11563] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449

    Awaiting development [GID-TA11542] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Troriluzole for spinocerebellar ataxia ID 6456

    Awaiting development [GID-TA11549] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064

    Awaiting development [GID-TA11594] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042

    Awaiting development [GID-TA11592] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036

    Awaiting development [GID-TA11596] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463

    Awaiting development [GID-TA11590] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457

    Awaiting development [GID-TA11576] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471

    Awaiting development [GID-TA11490] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466

    Awaiting development [GID-TA11583] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467

    Awaiting development [GID-TA11585] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468

    Awaiting development [GID-TA11581] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development